PATENT CLAIM ANALYSIS

Application Number: 16058512
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "665000"]

Abstract:
The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.

Claim (Index 22):
A pharmaceutical composition comprising:\n (a) {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof, (b) less than 1000 mg of metformin, and (c) at least one pharmaceutically acceptable carrier, excipient, diluent, or a mixture thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 1.66667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15687824', '14988143', '13114964', '14071976', '15983249']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7714122889549977
- 35 USC 102 Novelty (BERT): 0.5079594687412344
- Combined Prediction Score: 0.7450670069336214
- Mean Citation Score: 263.69637
- Max Citation Score: 305.7932
- Similarity Product: 266.056999831152

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test